Feed BHVN
BH

Biohaven BHVN · NYSE

$10.79 -5.60% (-$0.64)

Market cap
$1.73B
Enterprise value
$1.79B
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/FCF
-
EV/EBITDA
-
ROIC
-181.8%
Gross margin
-
Net margin
-
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
3.20
Free float
85.1%

About the company

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) is a biotechnology company focused on researching, developing, and commercializing therapeutic products for the treatment of neurological and psychiatric disorders. The company aims to discover novel drug candidates and innovative therapies for patients suffering from migraine, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and other neurological disorders. Biohaven is advancing and testing drugs in various stages of clinical trials and aspires to bring new therapeutic solutions to the field of neurological treatment. The company collaborates with academic and industry partners and focuses on innovation in the field of neuroscience. Biohaven Pharmaceutical Holding Company Ltd. (BHVN) shares may present an attractive investment opportunity for investors monitoring the biotechnology sector and seeking investments in a company with promising neurological treatment innovations and a strong commitment to addressing neurological disorders.

Sector

Healthcare

Industry

Biotechnology

CEO

Vladimir Coric

Employees

274

Headquarters

New Haven

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.